Avastin Follow-Up: Info from the FDA

By Rachel Walden |

On Friday, Christine posted, , with the news of and reactions to the FDA’s recent decision that Avastin (bevacizumab) should no longer be approved for use for breast cancer because “the agency has determined that the risks of the drug outweigh the benefits for this use.”

The FDA has with additional details about the recommendation, including their explaining the agency’s rationale, , , and .

Comments for this post are closed.